Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Nephros (NEPH) Research & Development (2016 - 2025)

Nephros (NEPH) has 16 years of Research & Development data on record, last reported at $338000.0 in Q3 2025.

  • For Q3 2025, Research & Development rose 79.79% year-over-year to $338000.0; the TTM value through Sep 2025 reached $1.2 million, up 38.75%, while the annual FY2024 figure was $906000.0, 3.78% up from the prior year.
  • Research & Development reached $338000.0 in Q3 2025 per NEPH's latest filing, up from $311000.0 in the prior quarter.
  • Across five years, Research & Development topped out at $556000.0 in Q1 2021 and bottomed at $60000.0 in Q4 2021.
  • Average Research & Development over 5 years is $288210.5, with a median of $254000.0 recorded in 2024.
  • Peak YoY movement for Research & Development: crashed 90.15% in 2021, then skyrocketed 496.67% in 2022.
  • A 5-year view of Research & Development shows it stood at $60000.0 in 2021, then surged by 496.67% to $358000.0 in 2022, then plummeted by 41.9% to $208000.0 in 2023, then rose by 21.15% to $252000.0 in 2024, then surged by 34.13% to $338000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Research & Development were $338000.0 in Q3 2025, $311000.0 in Q2 2025, and $295000.0 in Q1 2025.